Valerian
•Last Updated: September 28 2022
Valeriana officinalis, also known as valerian, is an herbal tea and supplement. It is commonly used for its sedative and anxiety-reducing effects.
Valerian is most often used for
Last Updated: September 28 2022
Valeriana officinalis is a plant, commonly referred to as valerian. Traditionally, valerian roots are brewed for tea or eaten for relaxation and sedation purposes. Though valerian is one of the more popular sedative teas, current evidence suggests it is not very effective.
Valerian's primary usage is to soothe anxiety or make it easier to go to sleep.
Though scientific measurements of sleep quality showed no difference between people that supplemented valerian and people that supplemented a placebo, many participants anecdotally reported that their sleep was better when supplementing valerian. Valerian may also aid with menustral pain, since it is a spasmolytic.
Valerian is thought to enhance the signalling of one of the main sedative neurotransmitters, gamma-aminobutyric acid (GABA).
It is possible that valerian has relaxing properties independent of any actual improvements in sleep quality. High doses of valerian have been noted to cause mild sedation. Further research is needed to confirm valerian's true effects on sleep.
Note that Valerian is also known as:
- Valerian
- Valeriana Officinalis
A standard dose of valerian is 450mg. Daytime supplementation should consist of 2 to 3 doses of 300mg.
Valerian supplements consist of the root, which is standardized to contain 0.8-1% valerenic acid.
Valerian should be taken an hour before bed. If valerian is being supplemented during the daytime, it should be taken with meals.
Research FeedRead all studies
2.^Salter S, Brownie STreating primary insomnia - the efficacy of valerian and hopsAust Fam Physician.(2010 Jun)
3.^Mathela CS, Tiwari M, Sammal SS, Chanotiya CSValeriana wallichii DC, a new chemotype from northwestern HimalayaJ Essent Oil Res.(2005 Nov-Dec)
4.^Navarrete A, Avula B, Choi YW, Khan IAChemical fingerprinting of valeriana species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detectionJ AOAC Int.(2006 Jan-Feb)
5.^Donovan JL, DeVane CL, Chavin KD, Wang JS, Gibson BB, Gefroh HA, Markowitz JSMultiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteersDrug Metab Dispos.(2004 Dec)
6.^Del Valle-Mojica LM, Ayala-Marín YM, Ortiz-Sanchez CM, Torres-Hernández BA, Abdalla-Mukhaimer S, Ortiz JGSelective Interactions of Valeriana officinalis Extracts and Valerenic Acid with {H}Glutamate Binding to Rat Synaptic MembranesEvid Based Complement Alternat Med.(2011)
7.^Schumacher B, Scholle S, Hölzl J, Khudeir N, Hess S, Müller CELignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptorsJ Nat Prod.(2002 Oct)
8.^Bodesheim U, Hölzl JIsolation and receptor binding properties of alkaloids and lignans from Valeriana officialis LPharmazie.(1997 May)
9.^Wang PC, Ran XH, Chen R, Li LC, Xiong SS, Liu YQ, Luo HR, Zhou J, Zhao YXVolvalerenone A, a new type of mononorsesquiterpenoid with an unprecedented 3,12-oxo bridge from Valeriana officinalisTetrahedron Lett.(2010)
10.^Marder M, Viola H, Wasowski C, Fernández S, Medina JH, Paladini AC6-methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNSPharmacol Biochem Behav.(2003 Jun)
11.^Fernández S, Wasowski C, Paladini AC, Marder MSedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalisPharmacol Biochem Behav.(2004 Feb)
12.^Goppel M, Franz GStability control of valerian ground material and extracts: a new HPLC-method for the routine quantification of valerenic acids and lignansPharmazie.(2004 Jun)
13.^Taibi DM, Bourguignon C, Gill Taylor AA feasibility study of valerian extract for sleep disturbance in person with arthritisBiol Res Nurs.(2009 Apr)
14.^Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, Sancho-Gómez P, Calbó-Caldentey C, Flores-Mateo GEffectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trialsSleep Med.(2010 Jun)
15.^Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, Rowland KM Jr, Zon RT, Lelindqwister NA, Nagargoje GG, Morgenthaler TI, Sloan JA, Loprinzi CLThe use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)J Support Oncol.(2011 Jan-Feb)
17.^Leathwood PD, Chauffard FAqueous extract of valerian reduces latency to fall asleep in manPlanta Med.(1985 Apr)
18.^Abourashed EA, Koetter U, Brattström AIn vitro binding experiments with a Valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptorsPhytomedicine.(2004 Nov)
19.^Müller CE, Schumacher B, Brattström A, Abourashed EA, Koetter UInteractions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptorsLife Sci.(2002 Sep 6)
20.^Maroo N, Hazra A, Das TEfficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trialIndian J Pharmacol.(2013 Jan-Feb)
21.^Melzer J, Schrader E, Brattström A, Schellenberg R, Saller RFixed herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatoform disorders: randomized, placebo-controlled pharmaco-clinical trialPhytother Res.(2009 Sep)
22.^Hellum BH, Hu Z, Nilsen OGThe induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytesBasic Clin Pharmacol Toxicol.(2007 Jan)
23.^Hellum BH, Hu Z, Nilsen OGTrade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytesBasic Clin Pharmacol Toxicol.(2009 Jul)
24.^Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah AIn vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypesClin Pharmacol Ther.(2005 May)
25.^Budzinski JW, Foster BC, Vandenhoek S, Arnason JTAn in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tincturesPhytomedicine.(2000 Jul)
26.^Mohamed ME, Frye RFInhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activitiesDrug Metab Dispos.(2011 Sep)
27.^Dietz BM, Mahady GB, Pauli GF, Farnsworth NRValerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitroBrain Res Mol Brain Res.(2005 Aug 18)
28.^Del Valle-Mojica LM, Ortíz JGAnxiolytic properties of Valeriana officinalis in the zebrafish: a possible role for metabotropic glutamate receptorsPlanta Med.(2012 Nov)
30.^Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DDMetabotropic glutamate receptors as novel targets for anxiety and stress disordersNat Rev Drug Discov.(2005 Feb)
31.^Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MKThe gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activityAnesth Analg.(2004 Feb)
32.^Cavadas C, Araújo I, Cotrim MD, Amaral T, Cunha AP, Macedo T, Ribeiro CFIn vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brainArzneimittelforschung.(1995 Jul)
33.^Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering SValerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificityNeuropharmacology.(2007 Jul)
34.^Benke D, Barberis A, Kopp S, Altmann KH, Schubiger M, Vogt KE, Rudolph U, Möhler HGABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extractsNeuropharmacology.(2009 Jan)
35.^Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp BModulation of GABAA receptors by valerian extracts is related to the content of valerenic acidPlanta Med.(2008 Jan)
36.^Wasowski C, Marder M, Viola H, Medina JH, Paladini ACIsolation and identification of 6-methylapigenin, a competitive ligand for the brain GABA(A) receptors, from Valeriana wallichiiPlanta Med.(2002 Oct)
37.^Mayer B, Springer EPsychoexperimental studies on the effect of a valepotriate combination as well as the combined effects of valtratum and alcoholArzneimittel-Forschung.(1974 Dec)
38.^Chambers J, Ames RS, Bergsma D, Muir A, Fitzgerald LR, Hervieu G, Dytko GM, Foley JJ, Martin J, Liu WS, Park J, Ellis C, Ganguly S, Konchar S, Cluderay J, Leslie R, Wilson S, Sarau HMMelanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1Nature.(1999 Jul 15)
39.^Vissiennon Z, Sichardt K, Koetter U, Brattström A, Nieber KValerian extract Ze 911 inhibits postsynaptic potentials by activation of adenosine A1 receptors in rat cortical neuronsPlanta Med.(2006 Jun)
40.^Rezvani ME, Roohbakhsh A, Allahtavakoli M, Shamsizadeh AAnticonvulsant effect of aqueous extract of Valeriana officinalis in amygdala-kindled rats: possible involvement of adenosineJ Ethnopharmacol.(2010 Feb 3)
41.^Rezvani ME, Mirnajafi-Zadeh J, Fathollahi Y, Palizvan MRAnticonvulsant effect of A1 but not A2A adenosine receptors of piriform cortex in amygdala-kindled ratsCan J Physiol Pharmacol.(2007 Jun)
42.^Hosseinmardi N, Mirnajafi-Zadeh J, Fathollahi Y, Shahabi PThe role of adenosine A1 and A2A receptors of entorhinal cortex on piriform cortex kindled seizures in ratsPharmacol Res.(2007 Aug)
43.^Miyasaka LS, Atallah AN, Soares BGValerian for anxiety disordersCochrane Database Syst Rev.(2006 Oct 18)
44.^Felgentreff F, Becker A, Meier B, Brattström AValerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activityPhytomedicine.(2012 Oct 15)
45.^Andreatini R, Sartori VA, Seabra ML, Leite JREffect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot studyPhytother Res.(2002 Nov)
46.^Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SRAn internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomniaMedicine (Baltimore).(2005 Jul)
47.^Taibi DM, Vitiello MV, Barsness S, Elmer GW, Anderson GD, Landis CAA randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomniaSleep Med.(2009 Mar)
48.^Leathwood PD, Chauffard F, Heck E, Munoz-Box RAqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in manPharmacol Biochem Behav.(1982 Jul)
50.^Schulz H, Stolz C, Müller JThe effect of valerian extract on sleep polygraphy in poor sleepers: a pilot studyPharmacopsychiatry.(1994 Jul)
51.^Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots ICritical evaluation of the effect of valerian extract on sleep structure and sleep qualityPharmacopsychiatry.(2000 Mar)
52.^Francis AJ, Dempster RJEffect of valerian, Valeriana edulis, on sleep difficulties in children with intellectual deficits: randomised trialPhytomedicine.(2002 May)
53.^Poyares DR, Guilleminault C, Ohayon MM, Tufik SCan valerian improve the sleep of insomniacs after benzodiazepine withdrawalProg Neuropsychopharmacol Biol Psychiatry.(2002 Apr)
54.^Diaper A, Hindmarch IA double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adultsPhytother Res.(2004 Oct)
55.^Bent S, Padula A, Moore D, Patterson M, Mehling WValerian for sleep: a systematic review and meta-analysisAm J Med.(2006 Dec)
56.^Taibi DM, Landis CA, Petry H, Vitiello MVA systematic review of valerian as a sleep aid: safe but not effectiveSleep Med Rev.(2007 Jun)
57.^Stevinson C, Ernst EValerian for insomnia: a systematic review of randomized clinical trialsSleep Med.(2000 Apr 1)
60.^Pakseresht S, Boostani H, Sayyah MExtract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind studyJ Complement Integr Med.(2011 Oct 11)
61.^Nam SM, Choi JH, Yoo DY, Kim W, Jung HY, Kim JW, Kang SY, Park J, Kim DW, Kim WJ, Yoon YS, Hwang IKValeriana officinalis extract and its main component, valerenic acid, ameliorate d-galactose-induced reductions in memory, cell proliferation, and neuroblast differentiation by reducing corticosterone levels and lipid peroxidationExp Gerontol.(2013 Sep 18)
63.^Savard J, Morin CMInsomnia in the context of cancer: a review of a neglected problemJ Clin Oncol.(2001 Feb 1)
64.^Palesh OG, Roscoe JA, Mustian KM, Roth T, Savard J, Ancoli-Israel S, Heckler C, Purnell JQ, Janelsins MC, Morrow GRPrevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology ProgramJ Clin Oncol.(2010 Jan 10)
65.^Davidson JR, MacLean AW, Brundage MD, Schulze KSleep disturbance in cancer patientsSoc Sci Med.(2002 May)
66.^Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MRNeuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancerJ Clin Oncol.(2008 Feb 20)
67.^Singh A, Kiran D, Singh H, Nel B, Singh P, Tiwari PPrevalence and severity of dysmenorrhea: a problem related to menstruation, among first and second year female medical studentsIndian J Physiol Pharmacol.(2008 Oct-Dec)
68.^Unsal A1, Ayranci U, Tozun M, Arslan G, Calik EPrevalence of dysmenorrhea and its effect on quality of life among a group of female university studentsUps J Med Sci.(2010 May)
69.^Tavallaee M, Joffres MR, Corber SJ, Bayanzadeh M, Rad MMThe prevalence of menstrual pain and associated risk factors among Iranian womenJ Obstet Gynaecol Res.(2011 May)
70.^Gilani AH, Khan AU, Jabeen Q, Subhan F, Ghafar RAntispasmodic and blood pressure lowering effects of Valeriana wallichii are mediated through K+ channel activationJ Ethnopharmacol.(2005 Sep 14)
71.^Mirabi P, Dolatian M, Mojab F, Majd HAEffects of valerian on the severity and systemic manifestations of dysmenorrheaInt J Gynaecol Obstet.(2011 Dec)
72.^Mirabi P, Mojab FThe effects of valerian root on hot flashes in menopausal womenIran J Pharm Res.(2013 Winter)
73.^Taavoni S, Ekbatani N, Kashaniyan M, Haghani HEffect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trialMenopause.(2011 Sep)
74.^Taavoni S, Nazem Ekbatani N, Haghani HValerian/lemon balm use for sleep disorders during menopauseComplement Ther Clin Pract.(2013 Nov)
75.^Bhatt C, Kanaki N, Nayak R, Shah GSynergistic potentiation of anti-anxiety activity of valerian and alprazolam by liquoriceIndian J Pharmacol.(2013 Mar-Apr)
76.^Cuellar NG, Ratcliffe SJDoes valerian improve sleepiness and symptom severity in people with restless legs syndromeAltern Ther Health Med.(2009 Mar-Apr)
77.^Takeshita S, Takeshita JA case of hyponatremia due to self-treatment of anxiety with a beverage containing valerian rootPrim Care Companion CNS Disord.(2013)